EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Generalized phase I‐II designs to increase long term therapeutic success rate

Peter F Thall iD, Yong Zang iD, Ying Yuan iD

Pharmaceutical Statistics · 2023-07 · 22 (4) · 692-706

DOI: 10.1002/pst.2301 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmaceutical Statistics, online erschienen am 11.04.2023. Verfasst von Peter F Thall und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, M.D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Research Design, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Designs for early phase dose finding clinical trials typically are either phase I based on toxicity, or phase I‐II based on toxicity and efficacy. These designs rely on the implicit assumption that the dose of an experimental agent chosen using these short‐term outcomes will maximize the agent's long‐term therapeutic success rate. In many clinical settings, this assumption is not true. A dose selected in an early phase oncology trial may give suboptimal progression‐free survival or overall survival time, often due to a high rate of relapse following response. To address this problem, a new family of Bayesian generalized phase I‐II designs is proposed. First, a conventional phase I‐II design based on short‐term outcomes is used to identify a set of candidate doses, rather than selecting one dose. Additional patients then are randomized among the candidates, patients are followed for a predefined longer time period, and a final dose is selected to maximize the long‐term therapeutic success rate, defined in terms of duration of response. Dose‐specific sample sizes in the randomization are determined adaptively to obtain a desired level of selection reliability. The design was motivated by a phase I‐II trial to find an optimal dose of natural killer cells as targeted immunotherapy for recurrent or treatment‐resistant B‐cell hematologic malignancies. A simulation study shows that, under a range of scenarios in the context of this trial, the proposed design has much better performance than two conventional phase I‐II designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignNeoplasmsHumansBayes TheoremReproducibility of ResultsComputer SimulationDose-Response Relationship, DrugMaximum Tolerated Dose

Stichwörter der Autor:innen

Bayesian designcell therapydose findingphase I-II clinical trial

Autor:innen und Institutionen

  • Department of Biostatistics, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics and Health Data Science, Center for Computational Biology and Bioinformatics, Indiana University, Indianapolis, Indiana, USA.

ORCID-Profile: Peter F Thall, Yong Zang, Ying Yuan

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • Ralph W. and Grace M. Showalter Research Trust Fund

Zitieren

APA

Thall, P. F., Zang, Y., & Yuan, Y. (2023). Generalized phase I‐II designs to increase long term therapeutic success rate. Pharmaceutical Statistics, 22(4), 692-706. https://doi.org/10.1002/pst.2301

Vancouver

Thall PF, Zang Y, Yuan Y. Generalized phase I‐II designs to increase long term therapeutic success rate. Pharmaceutical Statistics. 2023;22(4):692-706. doi:10.1002/pst.2301

BibTeX
@article{Thall2023,
  author = {Thall, Peter F and Zang, Yong and Yuan, Ying},
  title = {Generalized phase I‐II designs to increase long term therapeutic success rate},
  journal = {Pharmaceutical Statistics},
  year = {2023},
  volume = {22},
  number = {4},
  pages = {692--706},
  doi = {10.1002/pst.2301}
}
Kostenlos starten →